Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Coya Therapeutics (COYA) Operating Expenses (2022 - 2025)

Coya Therapeutics' Operating Expenses history spans 4 years, with the latest figure at $6.0 million for Q3 2025.

  • For Q3 2025, Operating Expenses rose 34.76% year-over-year to $6.0 million; the TTM value through Sep 2025 reached $24.6 million, up 17.62%, while the annual FY2024 figure was $20.8 million, 49.61% up from the prior year.
  • Operating Expenses for Q3 2025 was $6.0 million at Coya Therapeutics, down from $6.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $7.9 million in Q1 2025 and bottomed at $1.7 million in Q1 2022.
  • The 4-year median for Operating Expenses is $4.1 million (2024), against an average of $4.3 million.
  • The largest YoY upside for Operating Expenses was 108.98% in 2023 against a maximum downside of 5.57% in 2023.
  • A 4-year view of Operating Expenses shows it stood at $2.0 million in 2022, then surged by 108.98% to $4.2 million in 2023, then dropped by 2.5% to $4.1 million in 2024, then soared by 46.91% to $6.0 million in 2025.
  • Per Business Quant, the three most recent readings for COYA's Operating Expenses are $6.0 million (Q3 2025), $6.6 million (Q2 2025), and $7.9 million (Q1 2025).